BMB-101 is an innovative drug under development by Bright Minds Biosciences, designed to selectively target the 5-HT2C serotonin receptor. By activating this receptor, BMB-101 aims to address a range of neuropsychiatric conditions, including depression, anxiety, and other mood...

At Bright Minds Biosciences, we understand the crucial role that serotonin plays in regulating mood, appetite, sleep, and overall well-being. Serotonin, often referred to as the “feel-good” neurotransmitter, helps create a sense of calm and happiness. However, many people stru...

Bright Minds Biosciences has completed its Phase I first-in-human study of BMB-101 being developed for the treatment of refractory epilepsies, psychosis, addiction, and impulse control disorders. The three-part study assessed the pharmacokinetic (PK), tolerability, safety, and...